Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Sharpe

Showing results (41-50 of 208) with videos related to

Pageof 21
Sort By:
Nature|February 2, 2018
Don't reject evidence from CFS therapiesMichael Sharpe, Trudie Chalder, Jon Stone
Journal of Neurology, Neurosurgery, and Psychiatry|August 13, 2011
Functional weakness: clues to mechanism from the nature of onsetJon Stone, Charles Warlow, Michael Sharpe
Psychosomatic Medicine|January 11, 2011
Can neuroimaging help us to understand and classify somatoform disorders? A systematic and critical reviewMichael Browning, Paul Fletcher, Michael Sharpe
Psychosomatics|March 15, 2011
What do physicians think of somatoform disorders?Joel Dimsdale, Neelom Sharma, Michael Sharpe
Journal of Psychosomatic Research|September 26, 2003
Diagnosing major depression in medical outpatients: acceptability of telephone interviewsKathryn Allen, Ann Cull, Michael Sharpe
BMC Psychology|March 16, 2019
The PACE trial of treatments for chronic fatigue syndrome: a response to WILSHIRE et alMichael Sharpe, Kim Goldsmith, Trudie Chalder
Journal of Psychosomatic Research|December 15, 2004
Illness beliefs and locus of control: a comparison of patients with pseudoseizures and epilepsyJon Stone, Michael Binzer, Michael Sharpe
Journal of Psychosomatic Research|April 4, 2006
Bodily symptoms: new approaches to classificationMichael Sharpe, Richard Mayou, Jane Walker
Trials|April 1, 2009
The second Symptom Management Research Trial in Oncology (SMaRT Oncology-2): a randomised trial to determine the effectiveness and cost-effectiveness of adding a complex intervention for major depressive disorder to usual care for cancer patientsJane Walker, Jim Cassidy, Michael Sharpe, et al.
Nature|February 26, 2020
Don't reject evidence from CFS therapiesMichael Sharpe, Trudie Chalder, Jon Stone
Pageof 21

Showing results (41-50 of 208) with videos related to

Sort By:
Pageof 21
Nature|February 2, 2018
Don't reject evidence from CFS therapiesMichael Sharpe, Trudie Chalder, Jon Stone
Journal of Neurology, Neurosurgery, and Psychiatry|August 13, 2011
Functional weakness: clues to mechanism from the nature of onsetJon Stone, Charles Warlow, Michael Sharpe
Psychosomatic Medicine|January 11, 2011
Can neuroimaging help us to understand and classify somatoform disorders? A systematic and critical reviewMichael Browning, Paul Fletcher, Michael Sharpe
Psychosomatics|March 15, 2011
What do physicians think of somatoform disorders?Joel Dimsdale, Neelom Sharma, Michael Sharpe
Journal of Psychosomatic Research|September 26, 2003
Diagnosing major depression in medical outpatients: acceptability of telephone interviewsKathryn Allen, Ann Cull, Michael Sharpe
BMC Psychology|March 16, 2019
The PACE trial of treatments for chronic fatigue syndrome: a response to WILSHIRE et alMichael Sharpe, Kim Goldsmith, Trudie Chalder
Journal of Psychosomatic Research|December 15, 2004
Illness beliefs and locus of control: a comparison of patients with pseudoseizures and epilepsyJon Stone, Michael Binzer, Michael Sharpe
Journal of Psychosomatic Research|April 4, 2006
Bodily symptoms: new approaches to classificationMichael Sharpe, Richard Mayou, Jane Walker
Trials|April 1, 2009
The second Symptom Management Research Trial in Oncology (SMaRT Oncology-2): a randomised trial to determine the effectiveness and cost-effectiveness of adding a complex intervention for major depressive disorder to usual care for cancer patientsJane Walker, Jim Cassidy, Michael Sharpe, et al.
Nature|February 26, 2020
Don't reject evidence from CFS therapiesMichael Sharpe, Trudie Chalder, Jon Stone
Pageof 21